Cancer-specific inhibitors that reflect the unique metabolic needs of cancer cells are rare. Here we describe Gboxin, a small molecule that specifically inhibits the growth of primary mouse and human glioblastoma cells but not that of mouse embryonic fibroblasts or neonatal astrocytes. Gboxin rapidly and irreversibly compromises oxygen consumption in glioblastoma cells. Gboxin relies on its positive charge to associate with mitochondrial oxidative phosphorylation complexes in a manner that is dependent on the proton gradient of the inner mitochondrial membrane, and it inhibits the activity of F 0 F 1 ATP synthase. Gboxin-resistant cells require a functional mitochondrial permeability transition pore that regulates pH and thus impedes the accumulation of Gboxin in the mitochondrial matrix. Administration of a metabolically stable Gboxin analogue inhibits glioblastoma allografts and patient-derived xenografts. Gboxin toxicity extends to established human cancer cell lines of diverse organ origin, and shows that the increased proton gradient and pH in cancer cell mitochondria is a mode of action that can be targeted in the development of antitumour reagents.
Glioblastoma is the most aggressive and prevalent primary malignancy of the central nervous system 1, 2 . Current treatments, which are dominated by radiotherapy and chemotherapy, target proliferating tumour cells and induce potent toxic side effects by harming normal proliferating cells 3, 4 . It is possible that relatively quiescent cancer stem cells in tumours may evade conventional therapeutic strategies 3, 5, 6 . Cancer stem cells can have metabolic characteristics that set them apart from proliferating tumour and somatic cells. Although proliferative tumour cells rely on aerobic glycolysis (which is known as the Warburg effect), slow-cycling tumour cells may prefer mitochondrial respiration as a primary source of energy 4, 5, [7] [8] [9] .
Oxidative phosphorylation (OXPHOS) has a central role in cellular energy. The OXPHOS machinery consists of over 90 proteins that are encoded by both the nuclear and mitochondrial genomes. The OXPHOS electron transport chain comprises four complexes (I to IV) that transfer electrons from donors generated by the TCA cycle and fatty acid oxidation to oxygen. Complexes I to IV pump protons out into the mitochondrial intermembrane space, which increases the pH inside the inner mitochondrial membrane and forms a voltage gradient. Complex V (F 0 F 1 ATP synthase) uses the stored energy in the proton gradient to generate ATP. Reactive oxygen species, a byproduct of the electron transport chain and ATP production, can be mitigated by several mechanisms, including the mitochondrial permeability transition pore (mPTP) 10, 11 . Several studies have examined the potential vulnerability of the electron transport chain in cancer cells through the inhibition of complex I, and this, with further validation, may hold therapeutic promise [12] [13] [14] [15] [16] [17] .
Here we describe the compound Gboxin, which was isolated from a high-throughput chemical screen based on low-passage primary glioblastoma (GBM) cells. This screen was designed to filter out toxicity to wild-type proliferating cells and limit the lethality to affect only primary GBM stem-like cells. Cancer cells have an unusually high mitochondrial membrane potential and thus retain higher pH within the matrix [18] [19] [20] [21] . Gboxin targets unique features of mitochondrial pH in GBM and other cancer cells, independent of their genetic composition, and exerts its tumour-cell-specific toxicity in primary culture and in vivo.
High-throughput screen of primary GBM culture
Previous cell-based 'anticancer' drug screens have predominantly identified agents that interfere with mitosis, replication or DNA damage repair 22, 23 . To differentiate between cancer cells and cells that are dividing normally, we considered experimental features that afford improved physiological relevance, such as the use of primary earlypassage tumour cells, serum-free conditions and low oxygen tension (5%, normoxia). We used a spontaneous GBM mouse model with mutations in three GBM-relevant tumour suppressors (Trp53, Pten and Nf1), under recombination mediated by the human GFAP-cre transgene 24, 25 . Low-passage sphere cultures from multiple tumours were pooled to establish primary 'high-throughput GBM sphere' (HTS) cells, which were frozen as pooled aliquots and used for the entire screening process (see Supplementary Methods). We performed a chemical screen of 200,000 compounds, using a 96-h Cell-Titer-Glo protocol (Extended Data Fig. 1a ). To exclude nonspecific or anti-mitotic toxicity, a counter screen against primary low-passage mouse embryonic fibroblasts (MEFs), neonatal astrocytes and primary subventricular-zone neural stem and progenitor cells was performed. Sixty-one compounds emerged as specific inhibitors of HTS cells with half-maximal inhibitory concentrations (IC 50 ) in the nanomolar range, and therapeutic windows that ranged from 1 to 3 logs (data not shown). We tested the 61 compounds in S9 fraction and hepatocyte assays, which yielded 17 compounds that were further tested for chemical tractability (Extended Data Fig. 1a ).
Here we describe the properties of one lead compound, the benzimidazolinium Gboxin (IC 50 = 150 nM; Fig. 1a, b ), and its chemical derivatives, all of which specifically inhibit the growth of HTS cells but not that of cycling primary MEFs or astrocytes ( Fig. 1b Article reSeArcH and 24 h of exposure (Extended Data Fig. 1d ). Gboxin inhibits wildtype neural stem and progenitor cell growth, but with greater than tenfold-higher IC 50 values compared to HTS cells (Extended Data Fig. 1c ). Transcriptional microarray analysis after Gboxin treatment revealed specific and sustained changes in expression of the genes Atf4 and Survivin (also known as Birc5) (Extended Data Fig. 1e , f, Supplementary  Table 1 ) in HTS cells, and Gene Ontology analysis identified multiple upregulated ATF4 stress-response targets [26] [27] [28] (Extended Data Fig. 1e , f, Supplementary Table 1 ). Western blot analysis confirmed an HTSspecific increase in ATF4 protein at 3 and 6 h ( Fig. 1c , Extended Data Fig. 1g , h). We also investigated several cancer-associated signal transduction pathways after 6 h of Gboxin exposure, and found that ATF4 upregulation was temporally accompanied by a decrease in phosphorylated S6 (phospho-S6) levels ( Fig. 1c ). Within 24 h, HTS cells underwent cell cycle arrest, as shown by an increase in the ratio of G1 and G0 to S phase, and this was followed within 3 days by a molecular signature of apoptosis (Extended Data Fig. 1i , j). Thus, Gboxin elicits rapid and specific responses that lead to cell death in primary HTS cells, but that are not manifested in cycling primary MEFs or astrocytes.
Gboxin disrupts primary GBM cell metabolism
The microarray data showed a rapid and sustained transcriptional suppression of Txnip, which is a regulator of glucose uptake and consumption and a target of OXPHOS 29, 30 (Extended Data Fig. 1e ). We examined the status of the mitochondrial membrane potential, assayed by tetramethylrhodamine ethyl ester perchlorate (TMRE) stain, after an extended Gboxin treatment 31 , and found a reduced membrane potential in HTS cells but not in MEFs (Extended Data Fig. 1k , l). We next performed oxygen consumption rate (OCR) measurements, and found a dose-dependent Gboxin inhibition that was equally as potent as that of well-characterized inhibitors of OXPHOS ( Fig. 2a , Extended Data Fig. 2a ). Despite its lethality being unique to HTS cells, Gboxin also caused acute OCR depletion in MEFs and astrocytes ( Fig. 2a , Extended Data Fig. 2b ). However, prolonged (30-h) OCR measurement showed that MEFs and astrocytes fully recovered from this depletion (Extended Data Fig. 2c, d) . Consistent with the above data, the OXPHOS inhibitors rotenone, antimycin A and oligomycin A-all of which both acutely and chronically impede OCR in all cells-rapidly induced the expression of ATF4 in MEFs and astrocytes ( Fig. 2b , Extended Data Fig. 2e ). AMP-activated protein kinase (AMPK), a rheostat for ATP availability, is activated in response to OXPHOS inhibition, and Gboxin-treated HTS cells showed a rapid and robust increase in phospho-AMPK and its target, phospho-ACC-79 32 (Fig. 2c ). These data indicate that Gboxin causes an irreversible inhibition of OXPHOS in HTS cells but not in wild-type cells.
Gboxin interacts with respiratory chain proteins
Through structure-activity relationship studies 33 , we determined that the positive charge on Gboxin is essential for its activity (data not shown). We further identified an active analogue that was amenable to biotin moiety modification, which we name B-Gboxin (IC 50 = 1,530 nM for HTS cells; Extended Data Fig. 3a, b) . B-Gboxin conserves Gboxin properties, such as OCR inhibition, ATF4 induction and reduction in phospho-S6 protein (Extended Data Fig. 3c, d ). Biotin-mediated pull-down experiments using HTS cells that were pretreated with B-Gboxin, followed by electrophoresis, resolved multiple silver-stained bands that were absent or reduced when HTS cells were preincubated with unbiotinylated Gboxin, which indicates a Gboxin-specific interaction ( Fig. 3a ). Mass spectrometry analysis of eluate from pull-down samples from HTS cells that were treated with Gboxin, B-Gboxin or both confirmed this Gboxin-specific interaction, and further revealed a biased presence of mitochondrial proteins (Supplementary Table 2 ). We next purified mitochondria from pretreated HTS cells for pull-down and mass spectrometry analysis. Of the 58 proteins we detected, 12 were components of the OXPHOS machinery (Extended Data Fig. 3e , Supplementary Table 3 ); components from all of the OXPHOS complexes were present, and complex V was best represented (five proteins) (Extended Data Fig. 3e ). We confirmed OXPHOS-component interactions using antibodies against components of complexes I, II, IV and V (Fig. 3b , Extended Data Fig. 3f ), and showed that interactions between B-Gboxin and OXPHOS proteins occur within 10 min of administration (Extended Data Fig. 3g ).
Co-purification interactions between B-Gboxin and OXPHOS proteins in Gboxin-resistant cells are considerably weakened (or even absent), compared with those in HTS cells ( Fig. 3c ). Furthermore, the detection of interactions between B-Gboxin and OXPHOS proteins requires whole-cell preincubation and cannot be achieved with incubation of cell lysates (data not shown). Thus, the specific association of B-Gboxin with OXPHOS proteins may be related to the unique environment that is created by the proton gradient across the mitochondrial inner membrane of cancer cells. To test this, we assayed B-Gboxin-OXPHOS protein associations in HTS cells in the presence of proton-gradient inhibitors. Rotenone and carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), a hydrogen ionophore, each cause a rapid reduction in the mitochondrial inner-membrane proton gradient, and inhibit B-Gboxin interactions with OXPHOS proteins. Conversely, oligomycin A acutely increases the proton gradient, and augments interactions between B-Gboxin and OXPHOS proteins in primary MEFs and astrocytes (Extended Data Fig. 4a ). Several factors indicate that complex V is the functional target for Gboxin-mediated cell death. OCR data demonstrate that-similar to the complex V inhibitor oligomycin A-Gboxin OCR inhibition can be bypassed by the proton ionophore FCCP, whereas inhibitors of complex I and complex III cannot ( Fig. 2a , Extended Data Fig. 2a ). Furthermore, similar to oligomycin A, Gboxin causes an acute increase in mitochondrial membrane potential (Fig. 4a ). By contrast, antimycin A and rotenone cause an acute reduction in membrane potential (Fig. 4a ). Finally, comparison of gene expression in HTS cells after exposure to rotenone, antimycin A, oligomycin A or Gboxin shows that the profiles for oligomycin A and Gboxin are related (Extended Data Fig. 4b ).
Blunted mPTP activity in GBM cells
The B-Gboxin mitochondrial extract pull-down assays also identified the protein ADT2, which is a component of the mPTP (Supplementary  Table 3 )-an unselective voltage-dependent channel to molecules of molecular mass < 1.5 kDa 11, [34] [35] [36] . Excess reactive oxygen species inside the mitochondrion can be expelled by the transient opening of mPTP to reduce membrane potential 10 . mPTP activity was examined by membrane-potential assays using tetramethylrhodamine methyl ester perchlorate (TMRM) fluorescence intensity, and mPTP-specific blockade was achieved using the inhibitor cyclosporin A (CsA). Under basal conditions, MEFs respond to reactive oxygen species (H 2 O 2 ) by reducing membrane potential through the opening of mPTP. CsA inhibition of the pore increases the basal MEF membrane potential that, in the presence of reactive oxygen species, cannot be relieved (Fig. 4b ). By contrast, HTS cells show an increased basal membrane potential that remains unresponsive to H 2 O 2 or CsA 19, 21 (Fig. 4b ). CsA had no measurable effects on Gboxin function and toxicity in HTS cells (Extended Data Fig. 4c ); however, in MEFs the presence of CsA caused cells to become Gboxin-sensitive ( Fig. 4c ), which was accompanied by a rapid induction of ATF4 (Extended Data Fig. 4d ) and a strengthened association of OXPHOS proteins with B-Gboxin ( Fig. 4d ). To exclude possible off-target effects of CsA, we complemented the studies with siRNAs directed against cyclophilin D (CypD, encoded by the Ppif gene)-the mPTP target of CsA-and achieved similar results 37 (Extended Data Fig. 4e ). Thus, a functional mPTP is essential for resistance to Gboxin.
The Gboxin structure-activity relationship studies also yielded a functional analogue (which we name C-Gboxin (IC 50 = 350 nM)) that is suitable for live-cell ultraviolet crosslink conjugation and that can be probed with an azide-fluor via click chemistry 38 (Extended Data Fig. 5a-c) . As demonstrated by immunofluorescence colocalization with the OXPHOS complex II component SDHA, there is a high accumulation of C-Gboxin in the mitochondria of HTS cells (Extended Data Fig. 5d ). By contrast, resistant MEFs show a limited accumulation of mitochondrial C-Gboxin (Fig. 4e ), which is reversed by treatment with CsA (Fig. 4f) . These data verify the preceding biochemical data that demonstrate that Gboxin specifically accumulates in the mitochondria of cancer cells. Cyclosporin-mediated blockade of mPTP increases mitochondrial pH (Fig. 4b) , Gboxin accumulation and Gboxin association with OXPHOS proteins (Fig. 4d, f) , and causes cellular toxicity (Fig. 4c ) in previously resistant MEFs.
Gboxin toxicity extends to human tumour cells
We next tested Gboxin activity on three independent GBM primary mouse cultures (Extended Data Fig. 6a ) and three GBM patientderived cultures (Fig. 5a, Supplementary Methods Article reSeArcH 150 nM) than those of human GBM cells (about 1 μM)) ( Fig. 5a ), which indicates that blunted mPTP activity occurs in GBM cells of diverse origin [39] [40] [41] .
We also assessed the scope of Gboxin activity on well-annotated human cancer cell lines derived from diverse types of tumour ( Fig. 5b -e, and data not shown). Most cancer cell lines were Gboxin-sensitive and demonstrated therapeutic windows, in contrast to wild-type resistant MEFs and astrocytes (Fig. 5b) . OCR assays confirmed Gboxin-coupled respiration blockade in representative cell lines (Extended Data Fig. 6b-h) . Two cell lines exhibited Gboxin resistance: Daoy human medulloblastoma cells and primary mouse malignant peripheral nerve sheath tumour cells 42 . These resistant tumour cells acquired Gboxin sensitivity and increased associations between B-Gboxin and OXPHOS proteins after CsA inhibition of the mPTP (Fig. 5e, Extended Data Fig. 6i ). Given the diverse genotypic drivers present in the sensitive human GBM and cancer cell lines, it appears that Gboxin activity is not tied to the specific driver mutations used to generate the HTS cell screen (Nf1, Trp53 and Pten). Moreover, similar to MEFs, the two Gboxin-resistant cancer cell lines have a CsA-responsive functional mPTP.
Gboxin inhibits growth of mouse and human GBM
Through the structure-activity relationship studies, we identified a functional analogue (which we name S-Gboxin, IC 50 = 470 nM) (Extended Data Fig. 7a-h ) that retained excellent metabolic stability, enhanced plasma stability and pharmacokinetic properties (Extended Data Fig. 7d-g) and was suitable for in vivo studies. Antitumour activity was first assessed by daily S-Gboxin treatment at 10 mg kg −1 day −1 , beginning on day 3 or day 14 after allograft flank implantation of HTS cells (Fig. 6a, Extended Data Fig. 8a ). Mice treated with S-Gboxin showed reduced tumour volume, cellular density and proliferation, and increased rates of survival in comparison to mice treated with a vehicle control ( Fig. 6a-d , Extended Data Fig. 8a-d ). Tumours treated with S-Gboxin had reduced expression of the high-grade glioma makers GFAP and OLIG2 (Fig. 6b, Extended Data Fig. 8b ). Primary human GBM cells were also injected into flanks of immunocompromised mice in the presence of Matrigel. After visible tumours were detected at 3 days, S-Gboxin was administered daily at 10 mg kg −1 day −1 , which resulted in significant attenuation of growth and decreased cellular density compared with controls (Extended Data Fig. 8e-h) .
To overcome poor blood-brain barrier penetration, we used catheter delivery to test activity in intracranial tumours. Primary mouse GBM cells were orthotopically transplanted, followed by a two-week period to allow tumour seeding and recovery from surgery; after this, catheters were implanted at the site of injection to deliver S-Gboxin locally through subcutaneous minipumps (2.16 μg per day per mouse; see Supplementary Methods). Treatment with S-Gboxin inhibited tumour growth, as manifested by reduced haemorrhaging, cellular density and proliferation (Extended Data Fig. 8i-k) . Histopathological analysis further showed a reduced expression of the high-grade glioma markers (Extended Data Fig. 8j, l) .
We next tested two independent patient-derived xenograft (PDX) models. Freshly engrafted patient GBM (P0: denotes PDX passage 0) was collected from symptomatic PDX mice and homogenized (for patient tumour 1) or dissociated into single cells (for patient tumour 2), and orthotopically implanted into the brains of four mice, each without culturing or additional manipulations (P1: denotes PDX passage 1). Two weeks (patient tumour 1) or four weeks (patient tumour 2) later, minipumps were implanted to deliver vehicle or S-Gboxin to the tumour area. All mice treated with vehicle showed symptoms of morbidity first (at 41-65 days), and were killed for analysis. S-Gboxin inhibited GBM PDX growth, as manifested by general health status and reduced cellular density, cellular proliferation and expression of GBM markers (Fig. 6e , f, Extended Data Fig. 8m ). Despite daily in vivo delivery over a fourweek period or more, no weight loss (Extended Data Fig. 8n ) or overt signs of general health deficits were detected in mice that were treated with S-Gboxin (data not shown). We also examined the status of the subventricular-zone stem cell niche after intracranial treatment with S-Gboxin. A representative comparison of endogenous nestin staining from tumour-bearing mice treated with a vehicle control or with S-Gboxin showed no abnormalities or loss of nestin staining in the subventricular zone, despite the obvious reduction of nestin-positive cells within the treated tumour (Extended Data Fig. 8l ). Finally, primary cultures from residual tumours treated with S-Gboxin were tested for acquired Gboxin resistance. Four independent tumour primary cultures (two treated with S-Gboxin and two with vehicle controls) were tested for Gboxin and S-Gboxin sensitivity. All tumour-derived cultures retained full Gboxin sensitivity (Extended Data Fig. 9a, b) . Thus, the failure of S-Gboxin to completely abrogate in vivo tumour growth is probably the consequence of inefficient access to the tumour over time and not to acquired resistance through secondary mechanisms, such as the reactivation of mPTP function.
Discussion
The effective eradication of proliferating tumour cells does not always result in meaningful therapeutic value. One possible explanation may lie in tumour heterogeneity and the presence of resistant quiescent stem-like cells. Here we sought to identify candidate antitumour molecules that would not display toxicity towards normal cycling cells.
Multiple mitochondrial functions are modified to sustain the cancer cell and thus may, in turn, serve as cancer-specific therapeutic targets [43] [44] [45] [46] . Many studies have previously investigated OXPHOS complex I inhibitors as therapeutic targets for cancer, with varying results 13, 14, [47] [48] [49] . Whether these compounds will inhibit primary culture tumour cells or in vivo tumours within acceptable toxicity parameters remains to be fully determined 13, 14 . Gboxin, a complex V inhibitor, relies on its positive charge to accumulate inside GBM mitochondria with irreversible toxic effects through rapid and sustained blockade of mitochondrial respiration-coupled OXPHOS. Gboxin resistance in wild-type cells rests on the functional activity of the mPTP. This uncovers a mechanism of action for targeting tumour cells, which are dependent on the heightened proton gradient that is present across the inner mitochondrial membrane of GBM and the other cancer cells we tested 50 (Extended Data Fig. 10 ). The elucidation of the underlying causes of this apparent mPTP deficit in GBM and other Gboxin-sensitive cancer cells merits careful scrutiny, and may shed additional light on how alterations in the metabolism of cancer cells may be targeted.
Primary cultures established from residual treated-tumour explants continued to exhibit Gboxin toxicity, which suggests that improved delivery or coupling with additional antitumour agents may serve to completely eradicate tumour growth. The scope of Gboxin toxicity appears to be unrelated to specific driver mutations; the fact that its activity extends to human cancer cell lines opens the possibility that a subset of cancers beyond GBM may be susceptible to Gboxin and related targeting strategies.
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